Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
about
Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trialStudy design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein productsStatistical Considerations in the Design of Biosimilar Cancer Clinical Trials.Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors.Clinical experience with Zarzio® in Europe: what have we learned?G-CSF: filgrastim, lenograstim and biosimilars.Plerixafor and Filgrastim XM02 (Tevagastrim) as a first line peripheral blood stem cell mobilisation strategy in patients with multiple myeloma and lymphoma candidated to autologous bone marrow transplantation.Biosimilar rhG-CSFs: how similar are they?First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony- stimulating factorComparison of biosimilar filgrastim with a reference product: pharmacokinetics, pharmacodynamics, and safety profiles in healthy volunteers
P2860
Q34077184-BECD9D20-0777-4093-82B4-4535AA2EFB43Q35044368-8F426DA8-56A6-41A2-836D-66BA9BC8B929Q36411858-4D3C2FDA-5FF2-470A-873E-DDC37450C49EQ36951030-0C8CFE37-5806-41E4-B143-BD54896D3EEDQ37373201-9E04B3EE-758B-4D82-A32B-7940E2031D77Q38006021-52A309ED-313D-4833-B9C2-5A067427C0DFQ38082542-81D529C3-3B09-40E8-A784-72FE5AA521D8Q38125609-7327591C-3F54-47A0-8F19-02B4A24A327BQ38202661-44BFF58D-15C4-48BF-AF21-EF3B752A0A05Q44894394-F88B6C43-0916-4B22-B0AF-1852EB6F4730Q45788056-4060F6A7-A6CF-4134-B570-08CABE2C55DFQ57217646-840312D4-3BB7-4CD0-83B3-B6E4854842E8Q58806308-73C32BAB-7BC2-44AD-ADC0-67A4C3D60596
P2860
Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacokinetic profiles of a ...... om a randomized, phase I trial
@ast
Pharmacokinetic profiles of a ...... om a randomized, phase I trial
@en
Pharmacokinetic profiles of a ...... om a randomized, phase I trial
@nl
type
label
Pharmacokinetic profiles of a ...... om a randomized, phase I trial
@ast
Pharmacokinetic profiles of a ...... om a randomized, phase I trial
@en
Pharmacokinetic profiles of a ...... om a randomized, phase I trial
@nl
prefLabel
Pharmacokinetic profiles of a ...... om a randomized, phase I trial
@ast
Pharmacokinetic profiles of a ...... om a randomized, phase I trial
@en
Pharmacokinetic profiles of a ...... om a randomized, phase I trial
@nl
P2093
P2860
P1433
P1476
Pharmacokinetic profiles of a ...... om a randomized, phase I trial
@en
P2093
Cornelius F Waller
Miguel Bronchud
Rodeina Challand
Stuart Mair
P2860
P304
P356
10.1007/S00277-010-0961-X
P577
2010-04-29T00:00:00Z